Antiangiogenic action 16k hPRL in retinal microvessels
16k hPRL 在视网膜微血管中的抗血管生成作用
基本信息
- 批准号:7171798
- 负责人:
- 金额:$ 31.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-02-01 至 2008-11-30
- 项目状态:已结题
- 来源:
- 关键词:Adenovirus VectorAdenovirusesAdrenal GlandsAdultAffectAftercareAgeAge related macular degenerationAngiogenesis InhibitorsAnimalsApoptosisApoptoticAreaBiological AssayBlindnessBlood VesselsBlood capillariesBlood-Retinal BarrierBos taurusCD36 geneCapillary Endothelial CellCattleCell ProliferationCell membraneCell modelCellsChildCicatrixCo-ImmunoprecipitationsComputer softwareCyclophosphamide/Fluorouracil/PrednisoneDegenerative DisorderDevelopmentDiabetes MellitusDiabetic RetinopathyDiseaseEdemaElderlyEndothelial CellsEtiologyEyeFibroblast Growth Factor 2Fluorescence MicroscopyFluorescence Resonance Energy TransferGreen Fluorescent ProteinsHemorrhageHistologicHumanImageImmunoblottingIn VitroInduction of ApoptosisInjection of therapeutic agentLabelLifeLight CoagulationMAP Kinase GeneMeasurementMeasuresMediatingMedicineMembrane MicrodomainsModelingMusNeonatalOrgan Culture TechniquesOxygenPathologyPathway interactionsPatientsPharmacotherapyPhosphorylationPopulationPrincipal InvestigatorProlactinProteinsRadioimmunoassayRas InhibitorRas/RafRetinaRetinalRetinal DiseasesRetinal NeovascularizationRetinopathy of PrematurityReverse Transcriptase Polymerase Chain ReactionRoleSignal PathwaySignal TransductionSignaling MoleculeStagingTdT-Mediated dUTP Nick End Labeling AssayTestingTherapeutic AgentsTimeTissuesTreatment FactorUnited StatesVascular Endothelial Growth FactorsVascular EndotheliumVascularizationWestern BlottingWestern Worldbaseblood glucose regulationcapillarycaspase-3caveolin 1cell growthin vivointermolecular interactionmiddle agemodel developmentmutantneovascularizationprogramsproliferative diabetic retinopathyprotein protein interactionras GTPase-Activating Proteinsreceptorresearch studyretinal damagescavenger receptortwo-photon
项目摘要
DESCRIPTION: Aberrant neovascularization of the retina is a major cause of adult blindness associated with diabetic retinopathy. The 16 kDa fragment of human prolactin (16K hPRL) is a potent and specific antiangiogenic factor that inhibits neovascularization of the retina in the oxygen-induced retinopathy (OIR) model. In a variety of endothelial cell models, 16K hPRL inhibits VEGF- and bFGF-induced endothelial cell proliferation and activates apoptosis. We will determine the signaling pathways responsible for the antiangiogenic action of the 16K hPRL in the retina in vitro in bovine adrenal capillary endothelial cells (BAEC) and human retinal endothelial cells (HREC), and in vivo in the mouse OIR model. The inhibition of VEGF-induced endothelial cell proliferation by 16K hPRL is mediated via inhibition of Ras activation. We hypothesize that 16K hPRL inhibits Ras activation by stimulating the association of Ras with two Ras inhibitory proteins, Ras-GAP and Sprouty2 (Spry). In vitro we will study the protein-protein interactions between Ras-GFP and Ras-GAP-RFP and Spry2-RFP in living BAEC and HREC by measuring fluorescence resonance energy transfer (FRET) intensity in cellular compartments. Cells will be treated with VEGF and VEGF + 16K hPRL and signaling interactions measured in real-time. We hypothesize that the organization of signaling molecules occurs within calveolae. The calveolae will be identified by caveolin-1 (Cav-1-CFP) and the co-localization and FRET of signaling molecules measured in calveolae with the GFP and RFP donor/acceptor pair. Immunoblotting of proteins purified from cell compartments will be used to confirm results. We hypothesize that the 16K hPRL-induced inhibition of retinal neovascularization in the OIR model is mediated by the induction of apoptosis and inhibition of MAPK signaling. We will determine if intravitreal injection of an adenovirus (Ad) expressing 16K hPRL (16K-Ad) or a NulI-Ad into one eye activates apoptosis in areas of neovascularization measured by the TUNEL assay and a caspase-3 assay. We will utilize quantitative fluorescence microscopy to measure MAPK activation in areas of neovascularization in retinal whole mounts from the OIR model. MAPK activation will be assessed with a recently established assay that measures co-localization and FRET intensity of Ras-GFP and Raf-I-RFP. These studies will provide the basis for developing potent antiangiogenic factors for the treatment of abnormal neovascualization of the retina.
描述:视网膜异常新生血管形成是糖尿病视网膜病变引起成人失明的主要原因。人催乳素的16 kDa片段(16 K hPRL)是一种有效且特异性的抗血管生成因子,其在氧诱导的视网膜病变(OIR)模型中抑制视网膜的新血管形成。在多种内皮细胞模型中,16 K hPRL抑制VEGF和bFGF诱导的内皮细胞增殖并激活凋亡。我们将确定的信号通路负责的抗血管生成作用的16 K hPRL在视网膜中的牛肾上腺毛细血管内皮细胞(BAEC)和人视网膜内皮细胞(HREC),在体外和在体内的小鼠OIR模型。16 K hPRL对VEGF诱导的内皮细胞增殖的抑制是通过抑制Ras活化介导的。我们假设16 K hPRL通过刺激Ras与两种Ras抑制蛋白Ras-GAP和Sprouty 2(Spry)的结合来抑制Ras活化。在体外,我们将研究Ras-GFP和Ras-GAP-RFP和Spry 2-RFP之间的蛋白质-蛋白质相互作用在活的BAEC和HREC通过测量荧光共振能量转移(FRET)强度在细胞区室。将用VEGF和VEGF +16 K hPRL处理细胞,并实时测量信号传导相互作用。我们推测,组织的信号分子发生在calveolae。将通过小窝蛋白-1(Cav-1-CFP)和在小窝中测量的信号分子与GFP和RFP供体/受体对的共定位和FRET来鉴定小窝。将使用从细胞区室纯化的蛋白质的免疫印迹来确认结果。我们推测16 K hPRL诱导的OIR模型中视网膜新生血管的抑制是通过诱导细胞凋亡和抑制MAPK信号传导介导的。我们将确定玻璃体内注射表达16 K hPRL的腺病毒(Ad)(16 K-Ad)或NulI-Ad到一只眼睛中是否激活通过TUNEL测定和半胱天冬酶-3测定测量的新血管形成区域中的细胞凋亡。我们将利用定量荧光显微镜来测量来自OIR模型的视网膜全标本中新生血管形成区域中的MAPK活化。将用最近建立的测定Ras-GFP和Raf-I-RFP的共定位和FRET强度的测定来评估MAPK活化。这些研究将为开发有效的抗血管生成因子治疗视网膜异常新生血管提供基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD Ira WEINER其他文献
RICHARD Ira WEINER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD Ira WEINER', 18)}}的其他基金
Antiangiogenic action 16k hPRL in retinal microvessels
16k hPRL 在视网膜微血管中的抗血管生成作用
- 批准号:
7012255 - 财政年份:2005
- 资助金额:
$ 31.31万 - 项目类别:
Antiangiogenic action 16k hPRL in retinal microvessels
16k hPRL 在视网膜微血管中的抗血管生成作用
- 批准号:
6866094 - 财政年份:2005
- 资助金额:
$ 31.31万 - 项目类别:
相似海外基金
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
cGAS-STING 通路靶向具有 CD46 趋向性和 AFP 启动子的复制腺病毒条件性复制限制用于治疗肝细胞癌
- 批准号:
10436626 - 财政年份:2021
- 资助金额:
$ 31.31万 - 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
- 批准号:
10557162 - 财政年份:2021
- 资助金额:
$ 31.31万 - 项目类别:
Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
- 批准号:
21K08199 - 财政年份:2021
- 资助金额:
$ 31.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
- 批准号:
10330464 - 财政年份:2021
- 资助金额:
$ 31.31万 - 项目类别:
Structural characterization of nucleoprotein cores of human adenoviruses
人腺病毒核蛋白核心的结构表征
- 批准号:
9807741 - 财政年份:2019
- 资助金额:
$ 31.31万 - 项目类别:
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
- 批准号:
41625-2013 - 财政年份:2018
- 资助金额:
$ 31.31万 - 项目类别:
Discovery Grants Program - Individual
The therapeutic strategies with augmented replications of oncolytic adenoviruses for malignant mesothelioma
溶瘤腺病毒增强复制治疗恶性间皮瘤的治疗策略
- 批准号:
18K15937 - 财政年份:2018
- 资助金额:
$ 31.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
- 批准号:
41625-2013 - 财政年份:2017
- 资助金额:
$ 31.31万 - 项目类别:
Discovery Grants Program - Individual
Exploring the effects of nutrient deprivation on T cells and oncolytic adenoviruses, in order to create immune activators for tumour therapy
探索营养剥夺对 T 细胞和溶瘤腺病毒的影响,以创造用于肿瘤治疗的免疫激活剂
- 批准号:
1813152 - 财政年份:2016
- 资助金额:
$ 31.31万 - 项目类别:
Studentship
Research on detection of novel adenoviruses by genetic methods
新型腺病毒的基因检测研究
- 批准号:
16K09118 - 财政年份:2016
- 资助金额:
$ 31.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




